It should be rather more of a busy day on Wall Street today after thin volumes on Monday due to the Columbus Day holiday.
It has emerged that the group is potentially considering the sale of its consumer health unit.
The business posted US$3.4bn in revenue last year, which was "distinct enough" from the core business that there could potential for it to be more valuable outside the company.
Elsewhere, the biopharma firm Amgen Inc (NASDAQ:AMGN) saw shares nudge 0.11% lower after hours to US$ 185.25 after the group said the key FDA had accepted what's called a supplemental biologics license application for Prolia.
The drug is an antibody to treat osteoporosis, treatment-induced bone loss, and giant cell tumor of bone, among others.
Elsewhere, Clovis Oncology Inc (NASDAQ:CLVS) saw shares add 1.80% to US$83.50 after the bell, after it revealed that it had submitted a supplemental new drug application to the FDA for anti cancer agent rucaparib.
Also in pre-market, Imperva Inc (NASDAQ:IMPV) shares lost 2.53% on the day yesterday, and lost 1.69% after the bell to US$44.25 after it reported the resignation of its finance chief Terry Schmid.
Schmid named Aaron Kuan as the new person in the role on an interim basis effective November 16, 2017.